🔥🐔 BizChicken 🐔🔥
Companies Similar to Kiora Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Alector, Inc.
AL001, AL101, AL002, AL003, AL044
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.
About | Vision/Values | History | Leadership | Contact | Culture | Vision/Values | History | About | About | About | About | Careers | About | About
Symbol: ALEC
Recent Price: $1.72
Industry: Biotechnology
CEO: Dr. Arnon Rosenthal Ph.D.
Sector: Healthcare
Employees: 245
Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 415 231 5660
Leadership
- Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
- Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
- Marc Grasso, M.D., Chief Financial Officer
- Gary Romano, M.D., Ph.D., Chief Medical Officer
- Danielle Pasqualone, Ph.D., J.D., General Counsel
- Clare Hunt, M.B.A., Chief People Officer
- Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
- Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
- Norah Conway, Senior Vice President, Portfolio and Program Management
- Neil Berkley, M.S., M.B.A., Chief Business Officer
- Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
- Elizabeth Garofalo, M.D., Board Member
- Paula Hammond, Ph.D., Board Member
- Richard H. Scheller, Ph.D., Board Member
- David Wehner, Board Member
- Kristine Yaffe, M.D., Board Member
- Errol De Souza, Ph.D., Board Member
- Mark Altmeyer, M.B.A., Board Member
Last updated: 2024-12-31
Athira Pharma, Inc.
ATH-1017
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.
Symbol: ATHA
Recent Price: $0.55
Industry: Biotechnology
CEO: Dr. Mark J. Litton M.B.A., Ph.D.
Sector: Healthcare
Employees: 65
Address: 18706 North Creek Parkway, Bothell, WA 98011
Phone: 425 620 8501
Last updated: 2024-12-31
Eyenovia, Inc.
Optejet
Eyenovia, Inc. is focused on developing therapeutic solutions for ophthalmic conditions using its proprietary microdose array print platform and Optejet delivery system. It targets conditions like progressive myopia, presbyopia, and mydriasis.
Symbol: EYEN
Recent Price: $0.11
Industry: Biotechnology
CEO: Mr. Michael M. Rowe
Sector: Healthcare
Employees: 57
Address: 295 Madison Avenue, New York, NY 10017
Phone: 917 289 1117
Leadership
- Charles Mather, Chairman of the Board
- Ellen Strahlman, MD, MS, Independent Director
- Sean Ianchulev, MD, MPH, Director
- Michael Geltzeiler, Independent Director
- Rachel Jacobson, Independent Director
- Ram Palanki, PharmD, Independent Director
- Michael Rowe, Director
Last updated: 2024-12-31
Kiromic BioPharma, Inc.
ALEXIS-ISO-1, ALEXIS-PRO-1
Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.
Symbol: KRBP
Recent Price: $0.93
Industry: Biotechnology
CEO: Mr. Pietro Bersani CPA, J.D.
Sector: Healthcare
Employees: 35
Address: 7707 Fannin, Houston, TX 77054
Phone: 832 968 4888
Leadership
- Pietro Bersani, CPA, Director
- Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
- Scott Dahlbeck, MD, PharmD, Chief of Staff
- Brian Hungerford, Chief Financial Officer
- Michael Nagel, Chairperson
- Michael Catlin, Independent Director
- Pam Misajon, Independent Director
Last updated: 2024-12-31
ORIC Pharmaceuticals, Inc.
ORIC-533, ORIC-944, ORIC-114
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of cancers, focusing on overcoming resistance in chemotherapy and immunotherapy. Their product candidates target various cancer resistance mechanisms, including prostate cancer and epidermal growth factor receptor mutations.
Symbol: ORIC
Recent Price: $8.17
Industry: Biotechnology
CEO: Dr. Jacob M. Chacko M.B.A., M.D.
Sector: Healthcare
Employees: 107
Address: 240 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 388 5600
Last updated: 2024-12-31
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Aura Biosciences, Inc.
AU-011
Aura Biosciences, Inc. operates as a biotechnology company developing virus-like drug conjugates (VDC) platform for treating ocular and urologic oncology tumors, with a focus on AU-011 for choroidal melanoma.
About | About | Management | Directors | About | Contact | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: AURA
Recent Price: $8.13
Industry: Biotechnology
CEO: Dr. Elisabet de los Pinos Ph.D.
Sector: Healthcare
Employees: 88
Address: 85 Bolton Street, Cambridge, MA 02140
Phone: 617 500 8864
Leadership
- David Johnson, Chairman
- Elisabet de los Pinos, PhD, Chief Executive Officer
- Giovanni Mariggi, PhD, Director
- Antony Mattessich, Director
- Sapna Srivastava, PhD, Director
- Karan Takhar, Director
Last updated: 2024-12-31
Biora Therapeutics, Inc.
oral biotherapeutics
Biora Therapeutics, Inc., a biotechnology company, focuses on developing oral biotherapeutics using ingestible smart capsules for targeted delivery in the gastrointestinal tract and needle-free delivery into the intestinal mucosa.
About | Leadership | About | Contact | Contact | Careers | Careers | About | Careers | Careers | About | About
Symbol: BIOR
Recent Price: $0.22
Industry: Biotechnology
CEO: Mr. Aditya P. Mohanty M.B.A.
Sector: Healthcare
Employees: 58
Address: 4330 La Jolla Village Drive, San Diego, CA 92122
Phone: 855 293 2639
Leadership
- Adi Mohanty, MBA, Chief Executive Officer & Board Member
- Eric d’Esparbes, Chief Financial Officer
- Robyn Hatton, Head of Human Resources
- Ariella Kelman, MD, Chief Medical Officer
- James Knight, MBA, Head of Business Development
- Clarke Neumann, JD, General Counsel and Secretary
- Paul Shabram, MBA, Head of Technical Operations
- Sharat Singh, PhD, Head of Research
- Maria (Mimi) Villanueva CPMI, PPMC, Vice President, Product Development Operations & Program Management
- Jeffrey Alter, MBA, Board Chair
- Jeffrey Ferrell, Board Member
- Jill Howe, Board Member
- Brian Kotzin, MD, Board Member
- Lynne Powell, MBA, Board Member
- Bruce Sands, MD, MS, Advisory Board Chair
- Geert D’Haens, MD, PhD, Advisory Board Member
- Brian Feagan, MD, FRCPC, Advisory Board Member
- Séverine Vermeire, MD, PhD, Advisory Board Member
- Satish Rao, MD, PhD, Advisory Board Chair
- William Chey, MD, Advisory Board Member
- Anthony Lembo, MD, Advisory Board Member
- Mark Pimentel, MD, Advisory Board Member
Last updated: 2024-12-31
Kala Pharmaceuticals, Inc.
KPI-012, EYSUVIS, INVELTYS
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.
Contact | Careers | Jobs | Careers | Careers | Careers | Careers | Leadership | Careers | Contact | Careers | Careers | Careers | About
Symbol: KALA
Recent Price: $6.87
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Mark T. Iwicki
Sector: Healthcare
Employees: 43
Address: 1167 Massachusetts Avenue, Arlington, MA 02476
Phone: 781 996 5252
Last updated: 2024-12-31
Kodiak Sciences Inc.
KSI-301
Kodiak Sciences Inc., a clinical stage biopharmaceutical company based in Palo Alto, California, specializes in developing therapeutics for retinal diseases. Their lead product candidate, KSI-301, is a potential treatment for various retinal conditions and is currently in Phase IIb/III clinical trials.
Symbol: KOD
Recent Price: $9.97
Industry: Biotechnology
CEO: Dr. Victor Perlroth M.D.
Sector: Healthcare
Employees: 111
Address: 1200 Page Mill Road, Palo Alto, CA 94304
Phone: 650 281 0850
Last updated: 2024-12-31
Kiora Pharmaceuticals, Inc.
KIO-301
Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.
Symbol: KPRX
Recent Price: $3.30
Industry: Biotechnology
CEO: Dr. Brian M. Strem Ph.D.
Sector: Healthcare
Employees: 12
Address: 1371 East 2100 South, Salt Lake City, UT 84105
Phone: 781 788 8869
Last updated: 2024-12-31
Keros Therapeutics, Inc.
KER-050
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.
About | Management | Directors | Contact | About | Contact | Careers | Benefits | Careers | About | Benefits | About | Careers | Jobs | Careers | Careers | Careers
Symbol: KROS
Recent Price: $15.64
Industry: Biotechnology
CEO: Dr. Jasbir S. Seehra Ph.D.
Sector: Healthcare
Employees: 149
Address: 99 Hayden Avenue, Lexington, MA 02421
Phone: 617 314 6297
Leadership
- Jasbir Seehra, Ph.D., Board Member
- Keith Regnante, M.B.A., Chief Financial Officer
- Christopher Rovaldi, President, Chief Operating Officer
- Esther Cho, J.D., Senior Vice President, General Counsel
- John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
- Robin Wagner, Senior Vice President, Human Resources
- Carl L. Gordon, Ph.D., C.F.A., Board Member
- Jean-Jacques Bienaimé, M.B.A., Lead Independent Director
- Nima Farzan, M.B.A., Board Member
- Mary Ann Gray, Ph.D., Board Member
- Tomer Kariv, J.D., Board Member
- Julius Knowles, M.B.A., Board Member
- Ran Nussbaum, Board Member
- Alpna Seth, Ph.D., Board Member
Last updated: 2024-12-31
Korro Bio, Inc.
genetic medicines based on editing RNA
Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing to treat rare and widespread diseases. The company is based in Cambridge, Massachusetts and aims to provide clinical benefits through their innovative approach.
Symbol: KRRO
Recent Price: $38.11
Industry: Biotechnology
CEO: Mr. Ram Aiyar MBA, Ph.D.
Sector: Healthcare
Employees: 92
Address: One Kendall Square, Cambridge, MA 02139-1562
Phone: 781-315-4600
Last updated: 2024-12-31
Kintara Therapeutics, Inc.
VAL-083, REM-001
Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.
About | Leadership | Directors | About | About | About | About | Contact | Careers | About | About | About
Symbol: KTRA
Recent Price: $0.22
Industry: Biotechnology
CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.
Sector: Healthcare
Employees: 1
Address: 12707 High Bluff Drive, San Diego, CA 92130
Phone: 858 350 4364
Leadership
- Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
- Greg A. Johnson, (Acting) Head of Operations
- Laura Johnson, Director
- Tamara A. Favorito, Director
- Robert J. Toth, Jr., M.B.A., Director
Last updated: 2024-12-31
Kura Oncology, Inc.
ziftomenib and tipifarnib
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.
Symbol: KURA
Recent Price: $8.51
Industry: Biotechnology
CEO: Dr. Troy Edward Wilson J.D., Ph.D.
Sector: Healthcare
Employees: 142
Address: 12730 High Bluff Drive, San Diego, CA 92130
Phone: 858 500 8800
Last updated: 2024-12-31
Kymera Therapeutics, Inc.
novel small molecule therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
About | About | Leadership | Foundation | Contact | Culture | About | About | Leadership | Foundation | About | About | About | Culture | Culture | Culture | Culture | About | About
Symbol: KYMR
Recent Price: $39.32
Industry: Biotechnology
CEO: Dr. Nello Mainolfi M.D., Ph.D.
Sector: Healthcare
Employees: 184
Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472
Phone: 857 285 5300
Leadership
- Nello Mainolfi, Ph.D., Founder, President & CEO
- Jeremy Chadwick, Ph.D., Chief Operating Officer
- Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
- Jared Gollob, MD, Chief Medical Officer
- Bruce Jacobs, CFA, MBA, Chief Financial Officer
- Karen Weisbach, Head of People and Culture
- Juliet Williams, Ph.D., Head of Research
- Bruce Booth, DPhil, Chairman and Co-Founder
- Felix J. Baker, PhD, Lead Independent Director
- Jeff Albers, JD, MBA,
- Pamela Esposito, PhD,
- Gorjan Hrustanovic, PhD,
- John Maraganore, PhD,
- Leigh Morgan,
- Victor Sandor, MDCM,
- Elena Ridloff, CFA,
Last updated: 2024-12-31
Kezar Life Sciences, Inc.
KZR-616
Kezar Life Sciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer in the United States.
About | About | About | About | Directors | About | Contact | Contact | Careers | Careers | Careers | Leadership | About | About | About | About | About | About | About | News | About | Careers | Contact | Careers | Careers | Careers | About | About | About | About
Symbol: KZR
Recent Price: $6.82
Industry: Biotechnology
CEO: Dr. Christopher J. Kirk Ph.D.
Sector: Healthcare
Employees: 58
Address: 4000 Shoreline Court, South San Francisco, CA 94080
Phone: 650 822 5600
Leadership
- Christopher Kirk, PhD, Chief Executive Officer, Co-Founder
- Marc Belsky, Chief Financial Officer
- Mark Schiller, Chief Legal Officer
- Neel K. Anand, DPhil, SVP, Research and Drug Discovery
- Zung To, SVP, Clinical Development
- Gitanjali Jain, SVP, Investor Relations and External Affairs
- Michelle Greenman, VP, Global Regulatory Affairs
- Jim Kirchner, PhD, VP, CMC and Supply Chain
- Andrew Basham, VP, Legal Affairs
- Dave Braggs, VP, Quality Assurance
- Pattie Chiang, SVP, Corporate Controller
- Tony Muchamuel, VP, Pharmacology & Toxicology
- Kiruthi Palaniswamy, PharmD, VP, Medical Affairs
- Mary Rogers, VP, Financial Planning & Analysis
- Joe Tedrick, VP, Human Resources
- Jinhai Wang, PhD, VP, Drug Metabolism & Pharmacokinetics
- John Fowler, Co-Founder
- Graham Cooper, Board Member, Beam Therapeutics, Former CFO, Receptos
- Franklin Berger, Founder
- Elizabeth Garner, MD, MPH, Chief Science Officer
- Michael Kauffman, MD, PhD, President, Chief Executive Officer, and Director
- Micki Klearman, MD, Former Group Medical Director
- Courtney Wallace, Venture Partner
Last updated: 2024-12-31
Ocular Therapeutix, Inc.
Re Sure Sealant; DEXTENZA; OTX-TKI; OTX-TIC; OTX-CSI
Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for eye diseases using bioresorbable hydrogel-based technology, offering products like Re Sure Sealant and DEXTENZA.
About | About | Leadership | Directors | Contact | Careers | Benefits | Vision/Values | DEI | Careers | About | About | About | About | About | About | About | About | About | About
Symbol: OCUL
Recent Price: $8.35
Industry: Biotechnology
CEO: Dr. Pravin U. Dugel M.D.
Sector: Healthcare
Employees: 267
Address: 24 Crosby Drive, Bedford, MA 01730
Phone: 781 357 4000
Leadership
- Pravin U. Dugel, MD, Executive Chairman, President and CEO
- Karen-Leigh Edwards, PhD, MBA, Chief Operations Officer
- Peter Jarrett, PhD, Chief Technical Officer
- Donald Notman, Chief Financial Officer and Chief Operating Officer
- Nadia K. Waheed, MD, MPH, Chief Medical Officer
- Jeffrey S. Heier, MD, Chief Scientific Officer
- Steve Meyers, Chief Commercial Officer
- Tracy Smith, Vice President, Human Resources
- Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
- Peter K. Kaiser, MD, Chief Development Officer
- Todd Anderman, JD, Chief Legal Officer and Corporate Secretary
- Charles Warden, Lead Independent Director
- Adrienne Graves, PhD, Director
- Leslie Williams, Director
- Richard Lindstrom, MD, Director
- Seung Suh Hong, PhD, Director
- Merilee Raines, Director
Last updated: 2024-12-31
Outlook Therapeutics, Inc.
ONS-5010
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.
About | About | Leadership | Directors | About | Contact | Careers | Careers | Careers | Jobs | About | About
Symbol: OTLK
Recent Price: $1.86
Industry: Biotechnology
CEO: Mr. C. Russell Trenary III
Sector: Healthcare
Employees: 24
Address: Building F, Iselin, NJ 08852
Phone: 609 619 3990
Leadership
- Randy Thurman, Executive Chairman
- Yezan Haddadin, Member of the Board of Directors
- Kurt J. Hilzinger, Member of the Board of Directors
- Julia A. Haller, MD, Member of the Board of Directors
- C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
- Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
- Faisal G. Sukhtian, Executive Director
- Julian Gangolli, Member of the Board of Directors
- Gerd Auffarth, MD, Member of the Board of Directors
- Andong Huang, Vice President, Business Development
Last updated: 2024-12-31
60 Degrees Pharmaceuticals, Inc.
Arakoda
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the prevention and treatment of infectious diseases, including malaria preventive treatment with Arakoda and other therapeutic developments.
Symbol: SXTP
Recent Price: $1.27
Industry: Biotechnology
CEO: Dr. Geoffrey Stuart Dow
Sector: Healthcare
Employees: 3
Address: 1025 Connecticut Avenue NW, Washington, DC 20036
Phone: 202-327-5422
Last updated: 2024-12-31